NO20011356L - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents
Pyrrolopyrimidines as protein kinase inhibitorsInfo
- Publication number
- NO20011356L NO20011356L NO20011356A NO20011356A NO20011356L NO 20011356 L NO20011356 L NO 20011356L NO 20011356 A NO20011356 A NO 20011356A NO 20011356 A NO20011356 A NO 20011356A NO 20011356 L NO20011356 L NO 20011356L
- Authority
- NO
- Norway
- Prior art keywords
- pyrrolopyrimidines
- protein kinase
- kinase inhibitors
- inhibitors
- protein
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10083498P | 1998-09-18 | 1998-09-18 | |
US10083298P | 1998-09-18 | 1998-09-18 | |
US10094698P | 1998-09-18 | 1998-09-18 | |
US10083398P | 1998-09-18 | 1998-09-18 | |
PCT/US1999/021560 WO2000017203A1 (en) | 1998-09-18 | 1999-09-17 | Pyrrolopyrimidines as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20011356D0 NO20011356D0 (en) | 2001-03-16 |
NO20011356L true NO20011356L (en) | 2001-05-16 |
Family
ID=27493158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20011356A NO20011356L (en) | 1998-09-18 | 2001-03-16 | Pyrrolopyrimidines as protein kinase inhibitors |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1114053A1 (en) |
JP (1) | JP2002526500A (en) |
KR (1) | KR20010085824A (en) |
CN (1) | CN1335849A (en) |
AU (1) | AU753555C (en) |
BG (1) | BG105346A (en) |
BR (1) | BR9913887A (en) |
CA (1) | CA2344249A1 (en) |
CZ (1) | CZ2001960A3 (en) |
HK (1) | HK1039326A1 (en) |
HU (1) | HUP0200403A3 (en) |
ID (1) | ID29028A (en) |
IL (1) | IL141866A0 (en) |
NO (1) | NO20011356L (en) |
NZ (1) | NZ510588A (en) |
PL (1) | PL346700A1 (en) |
SK (1) | SK3842001A3 (en) |
TR (1) | TR200101186T2 (en) |
WO (1) | WO2000017203A1 (en) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
ATE336484T1 (en) | 1998-08-29 | 2006-09-15 | Astrazeneca Ab | PYRIMIDINE COMPOUNDS |
ES2274634T3 (en) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | PIRIMIDINE COMPOUNDS. |
US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
EP1382339B1 (en) | 1999-12-10 | 2007-12-05 | Pfizer Products Inc. | Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives |
CA2397575A1 (en) * | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
US7369946B2 (en) | 2000-03-29 | 2008-05-06 | Abbott Gmbh & Co. Kg | Method of identifying inhibitors of Tie-2 |
WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
CN100351253C (en) * | 2000-06-26 | 2007-11-28 | 辉瑞产品公司 | Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
AR035885A1 (en) | 2001-05-14 | 2004-07-21 | Novartis Ag | DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
WO2003076434A1 (en) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
JP2005538118A (en) | 2002-08-06 | 2005-12-15 | アストラゼネカ アクチボラグ | Condensed pyridine and pyrimidine with TIE2 (TEK) activity |
GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
JP2006509000A (en) | 2002-11-26 | 2006-03-16 | ファイザー・プロダクツ・インク | Method of treatment of graft rejection |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
RS20050692A (en) | 2003-03-12 | 2007-11-15 | Pfizer Production Inc., | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
AR045037A1 (en) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE. |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
JP2007511596A (en) * | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | Pyrrolopyrimidine compounds useful in the treatment of cancer |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
CA2553724A1 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
UA89493C2 (en) | 2004-04-02 | 2010-02-10 | Оси Фармасьютикалз, Инк. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
JP4842929B2 (en) | 2004-05-27 | 2011-12-21 | ファイザー・プロダクツ・インク | Pyrrolopyrimidine derivatives useful for cancer treatment |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
PE20060748A1 (en) * | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | INDOLCARBOXAMIDE DERIVATIVES AS KINASE INHIBITORS IKK2 |
CN101175755A (en) * | 2005-03-17 | 2008-05-07 | 诺瓦提斯公司 | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
EP1874769B1 (en) * | 2005-04-25 | 2011-09-14 | Merck Patent GmbH | Novel aza- heterocycles serving as kinase inhibitors |
ES2374450T3 (en) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | ANTI-BANGEOUS RESPONSE BIOLOGICAL MARKERS FOR KINNER INHIBITORS OF THE GROWTH FACTOR RECEIVER 1 SIMILAR TO INSULIN. |
AR056556A1 (en) | 2005-09-30 | 2007-10-10 | Astrazeneca Ab | IMIDAZO (1,2-A) PIRIDINE WITH CELLULAR ANTIPROLIFERATION ACTIVITY |
JP5116687B2 (en) * | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
AR057960A1 (en) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | BICYCLE PROTEIN QUINASE INHIBITORS |
EP2004645A2 (en) * | 2006-02-14 | 2008-12-24 | Vertex Pharmaceuticals, Inc. | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
EP2021338A1 (en) | 2006-05-09 | 2009-02-11 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
BRPI0814423B1 (en) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Kinase modulating compounds and pharmaceutical composition comprising the same |
BRPI0917459B1 (en) | 2008-08-20 | 2017-09-12 | Zoetis Services Llc | N-METHYL-1- [TRANS-4- [METHYL (7H-PYRROL [2,3-D] PYRIDOL [2,3-D] PYRIMIDINE COMPOUNDS, USE OF THESE IN THERAPY AND CRYSTALLINE AS N-METHYL-PYRIMIDIN -4-YL) AMINO] CYCLOHEXYL} METHANOSULPHONAMIDE |
DK2358720T3 (en) * | 2008-10-16 | 2016-06-06 | Univ California | Heteroarylkinaseinhibitorer fused-ring |
US8710104B2 (en) | 2008-11-07 | 2014-04-29 | Triact Therapeutics, Inc. | Catecholic butanes and use thereof for cancer therapy |
US20120016119A1 (en) * | 2009-01-22 | 2012-01-19 | Yasunori Tsuboi | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND |
JP2012518657A (en) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Combined anticancer treatment |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
JP2012519282A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
JP5656976B2 (en) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | Pyrrolotriazine compounds |
US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
WO2011109572A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110217309A1 (en) | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
JP2014507465A (en) * | 2011-03-08 | 2014-03-27 | ノバルティス アーゲー | Fluorophenyl bicyclic heteroaryl compounds |
JP2014519813A (en) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment |
AU2012283775A1 (en) | 2011-07-13 | 2014-01-23 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
UA115312C2 (en) | 2011-07-19 | 2017-10-25 | Мерк Шарп І Доум Б.В. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk- inhibitors |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
EP2809673B1 (en) | 2012-01-31 | 2016-11-02 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as bruton's tyrosine kinase inhibitors |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2014017659A1 (en) * | 2012-07-27 | 2014-01-30 | 独立行政法人理化学研究所 | Agent for treating or controlling recurrence of acute myelogenous leukemia |
MX2015003874A (en) | 2012-09-26 | 2015-12-16 | Univ California | Modulation of ire1. |
JP6255038B2 (en) | 2013-02-26 | 2017-12-27 | トリアクト セラピューティクス,インク. | Cancer treatment |
CA2923667A1 (en) | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
SG11201602421VA (en) | 2013-09-30 | 2016-04-28 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
JP6493218B2 (en) * | 2013-11-08 | 2019-04-03 | 小野薬品工業株式会社 | Pyrrolopyrimidine derivatives |
CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
CA2834528A1 (en) * | 2013-11-26 | 2015-05-26 | Pharmascience Inc. | Protein kinase inhibitors |
CN105916859A (en) | 2014-02-03 | 2016-08-31 | 卡迪拉保健有限公司 | Heterocyclic compounds |
EP3179991B1 (en) | 2014-08-11 | 2021-10-06 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
CN108883103A (en) * | 2015-12-02 | 2018-11-23 | 阿斯特来亚治疗有限责任公司 | Piperidyl nociceptin acceptor compound |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
AU2019340173B2 (en) * | 2018-09-13 | 2024-02-08 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
PE20221905A1 (en) * | 2019-10-11 | 2022-12-23 | Incyte Corp | BICYCLIC AMINES AS INHIBITORS OF CDK2 |
CN112961159B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidinopyrazole/pyrrole derivative and preparation method and application thereof |
CN112961158B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidinopyrazole/pyrrole derivative and preparation method and application thereof |
JP7504822B2 (en) | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | Pharmaceutical Compositions Containing Imidazopyridinone Compounds |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
CN117402161A (en) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | Sulfoxide imine compound with FGFR inhibition effect, pharmaceutical composition containing sulfoxide imine compound and application of sulfoxide imine compound |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3036390A1 (en) * | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
CA2100863A1 (en) * | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
CN1046731C (en) * | 1994-09-29 | 1999-11-24 | 诺瓦蒂斯有限公司 | Pyrrolo [2,3-d] pyrimidines and their use |
US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
CH690773A5 (en) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo (2,3-d) pyrimides and their use. |
WO1997032879A1 (en) * | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES |
US6051577A (en) * | 1996-03-15 | 2000-04-18 | Novartis Ag | N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof |
CN1134439C (en) * | 1997-03-19 | 2004-01-14 | 艾博特股份有限两合公司 | Pyrrolo [2,3D] pyrimidines and their use as tyrosine kinase inhibitors |
-
1999
- 1999-09-17 BR BR9913887-5A patent/BR9913887A/en not_active IP Right Cessation
- 1999-09-17 TR TR2001/01186T patent/TR200101186T2/en unknown
- 1999-09-17 JP JP2000574112A patent/JP2002526500A/en active Pending
- 1999-09-17 ID IDW20010652A patent/ID29028A/en unknown
- 1999-09-17 KR KR1020017003532A patent/KR20010085824A/en not_active Application Discontinuation
- 1999-09-17 CA CA002344249A patent/CA2344249A1/en not_active Abandoned
- 1999-09-17 HU HU0200403A patent/HUP0200403A3/en unknown
- 1999-09-17 NZ NZ510588A patent/NZ510588A/en unknown
- 1999-09-17 AU AU60484/99A patent/AU753555C/en not_active Ceased
- 1999-09-17 EP EP99969415A patent/EP1114053A1/en not_active Withdrawn
- 1999-09-17 PL PL99346700A patent/PL346700A1/en unknown
- 1999-09-17 CN CN99813217A patent/CN1335849A/en active Pending
- 1999-09-17 CZ CZ2001960A patent/CZ2001960A3/en unknown
- 1999-09-17 WO PCT/US1999/021560 patent/WO2000017203A1/en not_active Application Discontinuation
- 1999-09-17 IL IL14186699A patent/IL141866A0/en unknown
- 1999-09-17 SK SK384-2001A patent/SK3842001A3/en unknown
-
2001
- 2001-03-15 BG BG105346A patent/BG105346A/en unknown
- 2001-03-16 NO NO20011356A patent/NO20011356L/en not_active Application Discontinuation
-
2002
- 2002-01-11 HK HK02100227.3A patent/HK1039326A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HK1039326A1 (en) | 2002-04-19 |
HUP0200403A2 (en) | 2002-06-29 |
WO2000017203A1 (en) | 2000-03-30 |
HUP0200403A3 (en) | 2004-07-28 |
IL141866A0 (en) | 2002-03-10 |
PL346700A1 (en) | 2002-02-25 |
NO20011356D0 (en) | 2001-03-16 |
JP2002526500A (en) | 2002-08-20 |
CZ2001960A3 (en) | 2001-10-17 |
BR9913887A (en) | 2001-10-23 |
CN1335849A (en) | 2002-02-13 |
NZ510588A (en) | 2003-08-29 |
SK3842001A3 (en) | 2002-04-04 |
KR20010085824A (en) | 2001-09-07 |
AU753555C (en) | 2003-07-03 |
TR200101186T2 (en) | 2001-10-22 |
ID29028A (en) | 2001-07-26 |
EP1114053A1 (en) | 2001-07-11 |
CA2344249A1 (en) | 2000-03-30 |
AU753555B2 (en) | 2002-10-24 |
AU6048499A (en) | 2000-04-10 |
BG105346A (en) | 2001-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20011356L (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
NO20011575D0 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors | |
NO20011574D0 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinase inhibitors | |
DK1047694T3 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
ID30460A (en) | INHIBITORS, INHIBITORS, THYROCIN CINASE PROTEIN | |
NO20021239D0 (en) | Pteridinones as kinase inhibitors | |
ATE318603T1 (en) | PYRROLOTRIAZINE KINASE INHIBITORS | |
NO20023713D0 (en) | 2-benzothiazolyl-urea derivatives and their use as protein kinase inhibitors | |
NO20035728D0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
NO20041887L (en) | Benzomidazoles useful as protein kinase inhibitors | |
HUP0400300A3 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
ID24289A (en) | BENZOTIAZOL INHIBITOR-INHIBITOR TERININ CINASE PROTEIN | |
NO990124D0 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
NO990123D0 (en) | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
DK2020408T3 (en) | Pyrrole-substituted 2-indolinone as protein kinase inhibitor | |
DK1140840T3 (en) | omega-carboxyaryl-substituted diphenylureas as raf kinase inhibitors | |
NO20015065D0 (en) | Pyrazolobenzodiazepines as CDK2 inhibitors | |
DK0858452T3 (en) | Thiazole derivatives as protein kinase C inhibitors | |
ATE255114T1 (en) | TRICYCLIC PROTEIN KINASE INHIBITORS | |
ATE387448T1 (en) | 4,5-PYRAZINOXINDOLES AS PROTEIN KINASE INHIBITORS | |
ATE252547T1 (en) | MATRIXMETALLOPROTEINASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |